^
    Back
    Association details:
    Biomarker:KRAS G13D
    Cancer:Colon Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    A study to explore the effects of cetuximab alone or in combination with irinotecan in patients with an abnormal gene (KRAS) in their colon cancer cells.

    Excerpt:
    ...Prior confirmation of tumour KRAS status as either KRAS WT (with no mutations or changes in BRAF, NRAS, PIK3CA exon20) OR KRAS G13D mutation,6. ...
    Trial ID:
    2012-003638-18
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Mol Cancer
    Title:

    Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab

    Excerpt:
    ...cetuximab treatment was ineffective for the tumors driven by HCT8, which is consistent with the previous findings that KRAS-mutant tumors are insensitive to cetuximab (Figure  2C)….
    DOI:
    https://dx.doi.org/10.1186%2F1476-4598-13-141